Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: Results of a two-year placebo-controlled trial

Journal of Bone and Mineral Research

Volumn 30, Issue 1, 2015, Pages 30-38

  Engelke, Klaus ^a,b   Fuerst, Thomas ^c   Dardzinski, Bernard ^d   Kornak, John ^e   Ather, Shabana ^f   Genant, Harry K ^e   De Papp, Anne ^f  

^a Synarc Inc   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c SYNARC INC   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cortical Bone; Femur; Odanacatib; Qct

Indexed keywords

CALCIUM; COLECALCIFEROL; ODANACATIB; PLACEBO; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CALCIUM INTAKE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR; FEMUR NECK; HIP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; THICKNESS; TRABECULAR BONE; CLINICAL TRIAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; RADIOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIPHENYL COMPOUNDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMANS; MIDDLE AGED; POSTMENOPAUSE; VITAMIN D;

EID: 84919935442     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2292     Document Type: Article

References (15)

1. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP, Cathepsin K. its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol. 2011;7(8):447-56
2. Lewiecki EM. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs. 2009;12(12):799-809
3. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res. 2012; 27(11):2251-8
4. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26(2):242-51
5. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5): 937-47
6. Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res. 2012;27(3):524-37
7. Jayakar RY, Cabal A, Szumiloski J, et al. Evaluation of highresolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: A study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone. 2012;50(6): 1379-88
8. Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res. 2012;27(3):509-23
9. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. J Clin Endocrinol Metab. 2013;98(2): 571-80
10. Cheung A, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: Improvements in bone geometry, microarchitecture and estimated bone strength. J Bone Miner Res. 2014 Aug;29(8):1786-94
11. Kang Y, Engelke K, Kalender WA. A new accurate and precise 3-D segmentation method for skeletal structures in volumetric CT data. IEEE Trans Med Imaging. 2003;22(5):586-98
12. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-15
13. Genant HK, Libanati C, Engelke K, et al. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone. 2013;56(2):482-8
14. Nicks KM, Amin S, Melton LJ 3rd, et al. Three-dimensional structural analysis of the proximal femur in an age-stratified sample of women. Bone. 2013;55(1):179-88
15. Gerner B, Töpfer D, Museyko O, Engelke K. To improve the measurement of longitudinal changes of cortical thickness and cortical bone mineral density in QCT: A simulation study. [Poster session presented at: 17th Conference of Medical Image Understanding and Analysis (MIUA); 2013 July 17-19; University of Birmingham, Birmingham, UK; p. 199]. Available from: http://events.cs.bham.ac.uk/miua2013/MIUAproceedings.pdf.